We are live on ! Find out more
EPIX

ESSA Pharma

Delisted

EPIX was delisted on the 8th of October, 2025.

31 hedge funds and large institutions have $185M invested in ESSA Pharma in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,125% more call options, than puts

Call options by funds: $245K | Put options by funds: $20K

0.17% more ownership

Funds ownership: 79.2%79.37% (+0.17%)

6% less funds holding

Funds holding: 3331 (-2)

38% less capital invested

Capital invested by funds: $297M → $185M (-$112M)

40% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 10

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
31
Holders Change
-2
Holders Change %
-6.06%
% of All Funds
0.45%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
2
Increased
6
Reduced
10
Closed
4
Calls
$245K
Puts
$20K
Net Calls
+$225K
Net Calls Change
+$10K

EPIX Hedge Fund Activity: Q2 2024 in Review

31 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q2 2024, worth a combined $185M — down 38% from $297M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of EPIX and 2 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 6 added.

The largest buyer was Soleus Capital Management, adding an estimated $3.95M. The largest seller was Janus Henderson Group, cutting an estimated $1.07M.

  • 31 institutional investors held ESSA Pharma (EPIX) as of Q2 2024, down from 33 in Q1 2024.
  • Funds reported $185M of ESSA Pharma stock for Q2 2024, down 38% quarter-over-quarter.
  • 2 funds opened new ESSA Pharma positions in Q2 2024 and 4 closed out, a net change of -2 holders.
  • The largest ESSA Pharma buyer in Q2 2024 was Soleus Capital Management, an estimated $3.95M added.
  • The largest ESSA Pharma seller in Q2 2024 was Janus Henderson Group, an estimated $1.07M sold.

Based on aggregated 13F filings for Q2 2024.